News & Events

StageBio is Exhibiting at ARVO 2023

The StageBio team is looking forward to exhibiting and attending at the ARVO Annual Meeting & Expo in New Orleans, LA. The ARVO conference will provide attendees access to new research, educational and professional development programming and networking opportunities for anyone working in the area of eye and vision research.

StageBio is hosting a booth and our team is looking forward to connecting with you in person! We invite you to set up some time to connect with us at booth #1047. Bring plenty of questions and our team will be ready to share!

The ARVO Annual Meeting is the premiere gathering for eye and vision scientists at all career stages, students, and those in affiliated fields to share the latest research findings  and  collaborate on innovative solutions. This year’s theme is “The Beauty of Diversity in Science and Nature”. Attend ARVO this year to connect with over 10,000 vision researchers, scientists and clinicians while attending educational sessions, poster events and the opportunity to network with your peers and colleagues in the ocular and vision space.

Interested in meeting with our team at the event? Contact our team here.  See you at ARVO April 23-27!


About StageBio

StageBio is a leading provider of GLP-compliant necropsy, histology, pathology, and specimen archiving and biorepository services for the biopharmaceutical, medical device, academic, and contract research industries. The company operates four GLP laboratories as well as three GLP specimen archiving facilities in the U.S., along with one GLP laboratory in Europe. We will continue to make investments in facility and technology infrastructure to meet the growing demand for high-quality histopathology services globally. StageBio has a team of 30+ board-certified veterinary pathologists and more than 100 laboratory technicians on staff supporting our unified commitment to quality, scientific integrity, and client satisfaction. Learn more at

Back to Index

Learn more about StageBio’s COVID-19 response